CAPRISE study

1. To describe the proportion of APRI > 1.0 and FIB-4 scores > 2.67 among people who undergo routine liver function and full blood count testing through St Vincent’s Pathology service
2. To describe the socio-demographic distribution of people with elevated APRI and FIB-4 scores
3. To determine the number of Fibroscan referrals per month after the introduction of automated APRI and FIB-4 calculations on St Vincent’s pathology reports compared to prior to the intervention
4. To determine the number and proportion of people referred for a Fibroscan following an automated APRI score of > 1.0 and/ or FIB-4 score > 2.67 who attend their Fibroscan appointment within the study period
5. To determine the accuracy of APRI and FIB-4 for cirrhosis diagnosis among those who undergo Fibroscan at St Vincent’s Hospital.

2022-2024

Single arm health systems intervention study.

Liver cirrhosis and liver cancer have high mortality rates. 

Early detection of people with clinically silent liver cirrhosis and linkage to specialist care enables timely treatments to prevent deaths from complications of cirrhosis. It will also facilitate early enrolment into liver cancer surveillance programs to ensure liver cancer is diagnosed early, when still amenable curable treatments.